PDCD1 and neoplasm: In particular, anti-PD-1 antibodies on an IgG1 background have been shown to eliminate CD8+ tumour infiltrating lymphocytes leading to abrogated therapeutic efficacy, an effect which can be overcome using Fc-null mutants that lack the ability to bind FcγRs [166].